Cellular and Molecular Gastroenterology and Hepatology (Jan 2021)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Diseasesummary

  • Anna-Maria Globig,
  • Nikola Patricia Sommer,
  • Katharina Wild,
  • Josefine Schardey,
  • Katharina Zoldan,
  • Anne Kerstin Thomann,
  • Lucas-Alexander Schulte,
  • Rupert Schreiner,
  • Wolfgang Reindl,
  • Jochen Klaus,
  • Christoph Mathis Schempp,
  • Maike Hofmann,
  • Robert Thimme,
  • Tobias Boettler,
  • Peter Hasselblatt

Journal volume & issue
Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

Background & aims: The pathogenesis of chronic inflammatory bowel diseases (Crohn’s disease [CD] and ulcerative colitis) involves dysregulated TH1 and TH17 cell responses, which can be targeted therapeutically by the monoclonal antibody Ustekinumab directed against the joint p40 subunit of IL-12 and IL-23. These cytokines may also regulate the differentiation of T follicular helper (TFH) cells, which promote B cell function in germinal centers. However, the role of TFH cells in CD pathogenesis and impact of Ustekinumab therapy on TFH cell fate in patients are poorly defined. Methods: Lymphocytes were isolated from peripheral blood (n=45) and intestinal biopsies (n=15) of CD patients or healthy controls (n=21) and analyzed by flow cytometry to assess TFH cell phenotypes and functions ex vivo. In addition, TFH cell differentiation was analyzed in the presence of Ustekinumab in vitro. Results: TFH cell frequencies in the intestine as well as peripheral blood were associated with endoscopic as well as biochemical evidence of CD activity. CD patients with clinical response to Ustekinumab, but not those with response to anti-TNF antibodies, displayed reduced frequencies of circulating TFH cells in a concentration-dependent manner while the TFH phenotype was not affected by Ustekinumab therapy. In keeping with this notion, TFH cell differentiation was inhibited by Ustekinumab in vitro while TFH cell maintenance was not affected. Moreover, Ustekinumab therapy resulted in reduced germinal center activity in CD patients in vivo. Conclusions: These data implicate TFH cells in the pathogenesis of CD and indicate that Ustekinumab therapy affects TFH cell differentiation, which may influence TFH-mediated immune functions in UST-treated CD patients.

Keywords